Sucampo Pharma (SCMP) Tops Q2 EPS by 1c; Reiterates 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sucampo Pharmaceuticals (SCMP) PT Raised to $23 at Maxim Group on 2Q Report; 'Solid Revenues... Transformation Underway'
August 2, 2017 3:35 PM EDTMaxim Group raised its price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $23.00 (from $21.00) while maintaining a Buy rating, following the company's second quarter earnings announcement.
Analyst Jason Kolbert notes the company delivered fourth quarter earnings per share and revenues above consensus... More
